Pricing Log in Create free account

Karyopharm Therapeutics Inc. (KPTI) vs Soligenix Inc. (SNGX)

Karyopharm Therapeutics Inc. and Soligenix Inc. are both Biotechnology companies. Karyopharm Therapeutics Inc. and Soligenix Inc. are of similar size ($8.0M and $7.7M). Karyopharm Therapeutics Inc. grew revenue faster over the last twelve months: 6.81% against −50.4%. Soligenix Inc. has the higher net margin (0.00% vs −153.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 16 metrics below, Soligenix Inc. leads on 9 and Karyopharm Therapeutics Inc. on 7.

Valuation

Metric KPTI SNGX Biotechnology median
P/E n/m n/m 8.50
P/S 0.08 11.29 9.71
P/B n/m 0.84 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.17 0.64
EV/Sales 1.34 (3.73) 9.21
Earnings yield (3,634.56%) (211.20%) (33.15%)
Free cash flow yield (580.28%) (174.60%) (25.50%)

Profitability

Metric KPTI SNGX Biotechnology median
Gross margin 95.89% 0.00% 65.16%
Operating margin (56.17%) 0.00% 0.00%
Net margin (153.28%) 0.00% 0.00%
Free cash flow margin (44.57%) 0.00% 0.00%
Return on equity 78.98% (241.65%) (56.36%)
Return on assets (207.90%) (125.95%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric KPTI SNGX Biotechnology median
Revenue growth (TTM) 6.81% (50.37%) 6.02%
EPS growth (last fiscal year) (98.37%) 57.03% 30.26%
Revenue growth, 5-year CAGR 6.21% (51.88%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric KPTI SNGX Biotechnology median
Debt to equity (0.76) 0.00 0.00
Current ratio 0.79 2.77 4.72
Net debt to EBITDA (2.03) 0.67 0.96

Dividend

Metric KPTI SNGX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric KPTI SNGX Biotechnology median
Market cap 7.95m 7.73m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack